Posts tagged Hartaj Singh


Oppenheimer Stays Bullish on Sarepta Therapeutics Inc (SRPT) as the Stock Shows Signs of Weakness

Oppenheimer analyst Hartaj Singh is out with a new research note on shares of Sarepta Therapeutics Inc …

Oppenheimer Waits for Catabasis Pharmaceuticals Inc (CATB) to Present Longer Term Data in DMD

Yesterday evening, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) announced that lead candidate edasalonexent missed the primary endpoint …

BTIG Reiterates Buy on Ocular Therapeutix Inc Despite Clinical Setback

Ocular Therapeutix Inc (NASDAQ:OCUL) shares fell more than 50% on Friday, after the company’s most advanced asset, a …

BTIG Remains Bearish on Keryx Biopharmaceuticals (KERX) Despite Fexeric EU Approval; Reduces Price Target

BTIG analyst Hartaj Singh weighed in today with a pessimistic view on Keryx Biopharmaceuticals (NASDAQ:KERX), after the company announced …

Wall Street’s Best and Worst Calls of the First Quarter 2015

The first quarter of 2015 has come to a close and companies are still releasing …

BTIG Reiterates Neutral Rating On Keryx Biopharmaceuticals Following Q4 Earnings Release

BTIG’s healthcare analyst Hartaj Singh came out with a research note on Keryx Biopharmaceuticals (NASDAQ:KERX), after the company reported …

BTIG Remains Neutral On Keryx Biopharmaceuticals Following Earnings Update

In a research report issued Friday, BTIG analyst Hartaj Singh reiterated a Neutral rating on …

Show More